In the Pipeline: Recursion's Approach to AI and Machine Learning.

The article from GEN Biotechnology discusses Recursion's innovative approach to AI and machine learning in drug development. Recursion aims to revolutionize the drug discovery process by utilizing its Recursion Operating System, which integrates hardware, software, datasets, and proprietary tools to explore biology's complex search space. The company plans to announce clinical data from several pipeline candidates, including REC-994 for cerebral cavernous malformation, and is set to merge with Exscientia to further enhance its capabilities. Recursion's CEO, Chris Gibson, emphasizes the importance of AI in improving the efficiency and success rate of drug development, aiming to challenge the industry's low success rate through innovative approaches. [Extracted from the article]